Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds

Weekly injections of semaglutide medications can significantly reduce the risk of serious kidney outcomes, major cardiovascular events, and death among people with type 2 diabetes and chronic kidney disease. A new study shows that semaglutide cuts the risk of severe outcomes from diabetic kidney disease by about 24%. The study, conducted among about 3,500 people across multiple countries, found that kidney function declined more slowly, the risk of major cardiovascular events was lower, and the risk of death from any cause was reduced for those treated with semaglutide. Treatment with semaglutide showed benefits beyond the standard care for diabetes.